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Abstract
Purpose There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) patients. The objective of this study is to
investigate the potential of 18F-FDG-PET/ CT to predict mortality in IPF.
Methods A total of 113 IPF patients (93 males, 20 females, mean age ± SD: 70 ± 9 years) were prospectively recruited for 18F-
FDG-PET/CT. The overall maximum pulmonary uptake of 18F-FDG (SUVmax), the minimum pulmonary uptake or background
lung activity (SUVmin), and target-to-background (SUVmax/ SUVmin) ratio (TBR) were quantified using routine region-of-interest
analysis. Kaplan–Meier analysis was used to identify associations of PET measurements with mortality. We also compared PET
associations with IPF mortality with the established GAP (gender age and physiology) scoring system. Cox analysis assessed the
independence of the significant PET measurement(s) from GAP score. We investigated synergisms between pulmonary 18F-
FDG-PET measurements and GAP score for risk stratification in IPF patients.
Results During a mean follow-up of 29 months, there were 54 deaths. The mean TBR ± SD was 5.6 ± 2.7. Mortality was
associated with high pulmonary TBR (p = 0.009), low forced vital capacity (FVC; p = 0.001), low transfer factor (TLCO;
p < 0.001), high GAP index (p = 0.003), and high GAP stage (p = 0.003). Stepwise forward-Wald–Cox analysis revealed that
the pulmonary TBR was independent of GAP classification (p = 0.010). The median survival in IPF patients with a TBR < 4.9
was 71 months, whilst in those with TBR > 4.9 was 24 months. Combining PET data with GAP data (BPET modified GAP
score^) refined the ability to predict mortality.
Conclusions A high pulmonary TBR is independently associated with increased risk of mortality in IPF patients.
Keywords Interstitial lung disease . Positron-emission tomography and computed tomography . Fluorine-18 FDG
Introduction
Interstitial lung disease (ILD) has an incidence of ~57/100,000
per year and is associated with significant morbidity [1]. The
ILDs consist of a heterogeneous group of diseases with vary-
ing amounts of interstitial inflammation and fibrosis [2].
However, there is heterogeneity in outcome, with survival in
idiopathic pulmonary fibrosis (IPF) particularly poor. Some
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patients gradually deteriorate, some undergo stepwise pro-
gression, whilst others decline rapidly. Moreover, much of
the prognostic data heralds from an era when the criteria for
diagnosing IPF were less well and differently defined than at
present [2–4].
Positron emission tomography (PET) offers the ability to
non-invasively investigate cellular metabolism in vivo. PET
studies in animals have yielded valuable insights into the bi-
ology of IPF and ILD [5, 6], and there is encouraging evidence
that PETmay aid the development of therapeutic interventions
to treat these debilitating conditions [7]. It has recently been
demonstrated that18F-fluorodeoxyglucose (18F-FDG) PET
signal is consistently raised and can be objectively measured
in patients with IPF [8]. Moreover, these PET signals are
shown to be stable and reproducible [9].
The prevailing theory of IPF is that alveolar epithelial dam-
age results in a chronic wound-healing response that leads to
self-propagating scar formation and end-stage fibrosis [10].
18F-FDG uptake by tissues is a marker of glucose utilization,
correlating with tissue metabolism. Our hypothesis was that
although the cellular basis of the FDG-PET signal is unclear,
on-going metabolic activity, in areas of scarred lung, would
indicate a process that could be manipulated therapeutically.
In addition, a significant correlation between FDG-PETsignal
and disease progression would strengthen the validity and
usefulness of this signal as a novel biomarker in IPF [11].
With the use of current treatment (e.g., anti-fibrinolytic
therapy) in IPF patients [12, 13] and given the rationale for
recommending these drugs as set out in some guidelines [14,
15], it has been recently highlighted that there is an urgent
need for biomarkers and end points in order to develop ther-
apy and treatment regimens for patients with IPF [3].
In this study, we investigate the potential for baseline mea-
sures of pulmonary 18F-FDG PET signal to predict survival in
patients with IPF compared to the more establishedGAP (gen-
der age and physiology) prognostic score [16].
Methods
Patients
From 2008 to 2017, there were a total of 113 (93 male, 20
female, mean age 70 ± 9 years) prospectively and consecu-
tively consented patients with IPF who underwent 18F-FDG
PET/CT from a single institution. All patients underwent full
clinical assessment including multidisciplinary team (MDT)
review, baseline pulmonary function tests (PFTs), and high-
resolution computed tomography (HRCT) evaluation.
Infection and neoplasia were excluded on clinical and radio-
logical grounds. The diagnosis of IPF was made on clinico-
radiological grounds following MDT review. The study had
ethics board approval and all patients gave written informed
consent.
Patient follow-up
The patient follow-up period was defined from date of scan to
death (all causes, as previously adopted in prognostic studies
[16]) or 9 years. Patient survival was confirmed by the use of
patient charts, electronic database, primary health care physi-
cian records, or telephone interview.
PET/CT acquisition
PET/CT imaging was performed after the diagnosis was made
following MDT review described above and all images were
acquired on the same PET CT instrument (VCT PET/64-
detector CT instrument, GE Healthcare Technology,
Waukesha, WI, USA). Three imaging sequences of the thorax
were performed whilst the patient remained supine on the
table throughout. A CTwas performed for attenuation correc-
tion. Maintaining the patient position, a whole-body 18F-FDG
PETemission scan (8min per bed position) was performed 1 h
after injecting 200 MBq of 18F-FDG and covered an area
identical to that covered by CT. Next, maintaining the patient
position, a deep inspiratory breath-hold diagnostic high-
resolution CT (HRCT) was performed using the following
parameters: 64 × 1.25-mm detectors, a pitch of 0.53, and
1.25-mm collimation (120 kVp and 100 mAs).
Image analysis
Observers
PET images were analyzed by a PET radiologist and senior
PET technologist with > 5 years’ experience in quantifying
pulmonary 18F-FDG PET uptake in IPF. CT images were
reviewed by a dedicated thoracic radiologist, independent of
the PET CT analysis.
Image display and processing
All images were loaded onto an ADW (GE Healthcare
Technology, Waukesha, WI, USA) workstation. All datasets
underwent image processing as previously described in detail
[7]. Using a region of interest, the area of most intense pul-
monary 18F-FDG uptake was identified and the highest image
value (SUVmax) measured (see Fig. 1).
In addition, the region of pulmonary parenchyma with the
lowest SUV was identified as previously described and was
shown to have high inter- and intra-observer reproducibility
[7]. In all cases, this region was confirmed by the dedicated
thoracic radiologist to conform to morphologically normal
lung parenchyma on co-registered CT. The lowest image
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value (i.e., SUVmin) in this region was recorded as a measure
of the background lung uptake and in turn to calculate the lung
target-to-background ratio (TBR = SUVmax/SUVmin) [7].
TBR can be interpreted as a measure of variation of FDG
uptake in the lung where a TBR close to 1 indicates relatively
uniform uptake. In addition, tissue-to-blood ratios have been
reported in several studies to be highly correlated with Ki
[17–19], therefore we also measured lung-to-blood back-
ground levels by drawing an ROI as described by the
European Association of Nuclear Medicine position paper
[20], and thus BTBR blood^ was calculated as lung SUVmax
divided by average value of the blood SUVmean.
GAP calculation
GAP calculation based on the four variables (gender (G), age
(A), and 2 lung physiology variables (P) forced vital capacity
(FVC) and transfer factor (TLCO) as previously described
was computed [16]. This comprised a model using continuous
predictors (GAP calculator) and a simple point-scoring system
(GAP index), which varies from 0, potentially indicating a
good outcome, to 8, potentially indicating a worse outcome.
Based on the GAP index, the three stages (stages I, II, III)
identified are: GAP stage I included GAP index 0, 1, 2, 3;
GAP stage II included GAP index 4, 5; and GAP stage III
included GAP index 6, 7, 8.
Statistical analysis
Statistical analyses were performed using SPSS for Windows
version 19.0 (IBM, Armonk, NY, USA).
Univariate survival analysis
The relationships of SUVmax, SUVmin, TBR, and TBR blood
with patient survival were assessed using univariate Kaplan–
Meier (KM) survival analysis. Median values for these parame-
ters were used as thresholds (cut-offs) to separate the survival
plots (poor and good prognostic groups) and the difference in
the survival plots was further evaluated using non-parametric
log-rank test. KM curves for patients above and below the
median cut-off for each PET parameter were constructed to dis-
play the proportion of patients surviving at a given time.
Cross-validation
Although the use of median value as a cut-off is unbiased, to
further reduce bias, cross-validation was undertaken for each
of the significant univariate PET markers of survival within
the respective patient sub-group [21]. Because of the sample
size, cross-validation could not be carried out on the basis of a
sample split (training and validation). Instead, the statistically
recognized k-fold (e.g., k = 4 in our study) cross-validation
procedure was carried out [21]. See Supplemental Material
for further detail.
Multivariate Cox regression analysis
Multivariate step-wise forward Wald–Cox regression was
used to determine which significant cross-validated PET pa-
rameters (SUVmax, SUVmin, TBR, and TBR blood) were in-
dependent of the GAP (GAP index and GAP stage) parame-
ters in predicting patient survival.
Modeling PET data with GAP analysis
The GAP scores were reclassified and modified based on the
PET parameters to ascertain if the combinations were syner-
gistic and improved the ability to predict survival.
For the PET-modified GAP calculation, we proposed
adding a fourth PET variable (SUVmax or SUVmin or TBR
or TBR blood that demonstrated the best prognostic ability
in our study, based on the above univariate Kaplan–Meier
survival analysis, cross-validation, and multivariate Cox re-
gression analysis) to the existing GAP index calculation. For
each patient, the best PET marker was binarized, based on the
median cut-off, as an adverse (coded as 1) or favorable (coded
as 0) PET signal similar to the coding employed in GAP cal-
culation. This was further added to the existing GAP index
calculation where the modified GAP index ranged from 0 to 9.
For example, if a patient with original GAP index B0^ had an
adverse PET marker i.e., B1^, the modified GAP index would
be B0 + 1^ = B1^. Conversely, if the patient with original GAP
Fig. 1 Co-registered PET (a) and
CT (b) of a patient with IPF
showing region of interest
placement as part of measuring
maximal pulmonary 18F-FDG
uptake [7]. The dark grey/black
regions are regions of high18F-
FDG metabolism on the PET
image (a)
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index B0^ had a favorable PET marker i.e., B0^, the modified
GAP index would be B0 + 0^ = B0^. So the Bnew^ modified
GAP index (mGAP) ranged from 0 to 9 in comparison to the
original GAP index, which ranged from 0 to 8. Based on the
mGAP index, we redefined the mGAP stages (stages I, II, III)
as follows: mGAP stage I includes mGAP index 0, 1, 2, 3;
mGAP stage II includesmGAP index 4, 5, 6; andmGAP stage
III includes mGAP index 7, 8, 9.
A second PET altered (risk stratified) GAP model was also
formulated where GAP stage was risk stratified (S-GAP) is
presented in the Supplemental Section.
C-index (goodness of fit)
To further assess how good the modified GAP stage
was at predicting a binary outcome (mortality) in com-
parison to GAP stage, the concordance statistic (C-index
or C-statistic) was measured as the area under the re-
ceiver operating characteristic (ROC) curve along with
the 95% confidence interval. In all analyses, p values <
0.05 were considered significant.
Results
There were 113 IPF patients in total. Eight percent of patients
were known to have a co-morbidity of cancer, 18% cardiovas-
cular disease 6% diabetes and 41% other diseases. Twenty
patients were known to have a history of anti-fibrotics, a fur-
ther 44% had a trial of steroids, and 17% immunosuppres-
sants, but not at the time of scanning. The mean ± 1 SD
follow-up period was 29 ± 25.2 months. There were 54 deaths
during the follow-up. The mean ± SD for SUVmax was 3.4 ±
1.4, SUVmin (background lung activity) was 0.7 ± 0.2 and the
mean TBR 5.6 ± 2.7 (Fig. 2).
The mean ± SD for FVC (percentage predicted) was
74.0% ± 18.2. The mean ± SD for TLCO (percentage predict-
ed) was 45.3 ± 14.4. GAP analysis was performed on 112
patients as FVC was unobtainable in one patient. KM analysis
showed that patients that demonstrated a high pulmonary
FDG uptake value had poorer survival scores (Table 1). Of
the 14 patents who were treated with pirfenidone and six who
were treated with nintedanib, no statistically significant sur-
vival difference was detected in these groups.
Of the 113 IPF patients, there was a significant association
(Fig. 3a) between uptake of pulmonary 18F-FDG and survival
(TBR, p = 0.009, before cross-validation), where patients be-
low the median cut-off (< 4.9) had a better prognosis than
patients with a TBR > 4.9 (hazard ratio: 2.1, 95% CI: 1.2–
3.6). After the fourfold cross-validation, the median cut-off
for each of the individual (four) folds was found to be the
same as the entire population, whereby patients below the
median cut-off (< 4.9) had a better prognosis than patients
with a TBR > 4.9 had worse prognosis (hazard ratio: 2.1,
95% CI: 1.2–3.6).
Patients with a TBR below a threshold of 4.9 had a 3-year
survival of > 65% compared to a 3-year survival of < 35% for
patients with a TBR above the threshold. Below the threshold,
~ 75% survived at 2 years and ~ 50% at 5 years, whilst sur-
vival was ~ 50 and 30%, respectively, above the threshold.
The 50% mortality (median survival) below the threshold was
~ 6 years, whilst above the threshold it was ~ 2 years.
There was a significant association (Fig. 3b) between GAP
Bindex^ and survival (GAP index, p = 0.003), where patients
Fig. 2 Box plots highlights the
distribution of the individual PET
markers (SUVmax, SUVmin, TBR)
for the entire patient population
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below the median cut-off (< 4) had good prognosis and pa-
tients > 4 had poor prognosis with a hazard ratio of 2.9 (95%
CI: 1.4–5.9).
In patients with a GAP index below a threshold of 4, ~ 80%
survived at 3 years, and ~ 45% at 3 years above the threshold.
In patients with a GAP index below a threshold of 4, ~ 86%
survived at 2 years and ~ 56% at 5 years, whilst survival was ~
55 and 35%, respectively, above the threshold. The 50% mor-
tality below the threshold was greater than 8 years whilst
above the threshold it was less than 2.5 years.
There was a significant association (Fig. 3c) between GAP
stage and survival (GAP stage, p = 0.003), where patients be-
low the median cut-off (< II) had good prognosis and patients
> II had poor prognosis with a hazard ratio of 2.9 (95% CI:
1.4–5.9).
In patients with a GAP Bstage^ below a threshold of II, ~
75% survived at 3 years whilst survival was ~ 40% above the
threshold. In patients with a GAP stage below a threshold of II
~ 86% survived at 2 years and ~ 56% at 5 years, whilst sur-
vival was ~ 55 and 35%, respectively, above the threshold.
The 50% mortality below the threshold was greater than 8
years whilst above the threshold it was less than 2.5 years.
The effect of the individual components of GAP (FVC and
TLCO) on PET survival stratification are shown in the
Supplementary Section.
Cox analysis to assess the independence of PET (TBR)
and GAP
PET parameter (TBR) was independent of GAP analysis. By
including TBR and GAP index in a Cox regression model,
TBR (median threshold > 4.9, HR: 2.092, 95% CI: 1.192–
3.674, p = 0.010) and GAP Index (median threshold > 4,
HR: 2.894, 95% CI: 1.409–5.945, p = 0.004) were both inde-
pendent predictors of survival.
By including TBR and GAP stage in a Cox regression
model, TBR (median threshold > 4.9, HR: 2.092, 95% CI:
1.192–3.674, p = 0.010) and GAP stage (median threshold:
> II, HR: 2.894, 95% CI: 1.409–5.945, p = 0.004) were both
independent predictors of survival.
Modeling PET-derived TBR by combining with GAP
analysis
There was synergy in survival associations (Tables 2 and 3,
Fig. 4, and Supplementary Table 1 see below).
PET-modified GAP calculation
The findings from the modified GAP using the TBR are pre-
sented in Table 3. It shows improved risk stratification over
the original GAP analysis and this additional benefit is further
shown in the ROC analysis in the next section below.
C-index
Area under the ROC curve (AUC) along with the 95% confi-
dence interval and p value for GAP stage and m-GAP stage
are as follows: 0.667 (0.567–0.767, p = 0.002) and 0.694
(0.598–0.791, p < 0.001) demonstrates increased ability of
m-GAP to predict patient mortality.
Discussion
In a population of 113 IPF patients, we have shown that base-
line objective measures of 18F-FDG uptake on PETare related
to patient survival. High pulmonary 18F-FDG uptake (TBR)
was associated with poor survival and was independent of
GAP stage. The GAP classification in our population was also
a strong survival predictor, but as is recognized, many patients
were unable to perform TLCO and PFTs can be skewed in IPF
patients with emphysema. Moreover, the GAP classification
measurements were synergistic with the prognostic potential
of lung pulmonary 18F-FDG uptake. As shown in Table 3
above, PET signal reclassifies a subset of patients at GAP
stage 1, as modified GAP stage 2 despite their relatively pre-
served lung function. Thus, even in groups of patients with
good PFTs, the pulmonary 18F-FDG uptake could identify
sub-populations of patients that would perform poorly. This
may have clinical implication as treatment recommendations
can depend on PFT performance [14, 15]. As such, pulmonary
18F-FDG uptake measured with PET is a potential prognostic
biomarker in IPF.
Table 1 Summary of the cohort associations with survival
incorporating the components of GAP analysis. PET (SUVmax, SUVmin,
TBR and TBR blood), age, gender, FVC, TLCO, and GAP (index and
stage) parameters, median cut-off (direction indicates poor prognosis),
hazard ratio (HR), 95% confidence interval (CI) and their associationwith
mortality (as assessed by log rank test from Kaplan–Meier analysis).
Statistically significant results are shown in bold.
Parameter IPF
Median HR (95% CI) p value
SUVmax > 3.1 1.3 (0.8–2.3) 0.317
SUVmin > 0.6 1.2 (0.7–2.3) 0.490
TBR > 4.9 2.1 (1.2–3.6) 0.009
TBR blood > 2.1 1.5 (0.9–2.6) 0.147
Age > 71.0 1.5 (0.9–2.7) 0.138
Gender Male 1.6 (0.7–3.7) 0.275
FVC < 72.5% 2.5 (1.4–4.5) 0.001
TLCO < 45.0% 3.4 (1.8–6.8) <0.001
GAP index > 4 2.9 (1.4–5.9) 0.003
GAP stage > II 2.9 (1.4–5.9) 0.003
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The synergies between PET and GAP (Table 3 and
Supplemental Table 1) are interesting. In GAP stage IIITable 2 Three-year mortality for the univariate PET, PFT, and GAP
indices as stratified based on above/below the threshold identified in
Table 1
3-year mortality
TBR <median, (n = 56) 35%
TBR > median, (n = 57) 70%
GAP I (n = 35) 24%
GAP II (n = 50) 56%
GAP III (n = 27) 65%
FVC >median (n = 56) 29%
FVC < median (n = 56) 68%
TLCO > median (n = 45) 19%
TLCO < median (n = 47) 73%
Table 3 Comparison between original GAP 3-year mortality PET ver-
sus PET modified GAP Stage (mGAP). The PET modified GAP stage
classification shows improved risk stratification compared to GAP on its
own especially in the stage I and III groups
3-year mortality
GAP I (n = 35) 24%
mGAP I (n = 24) 9%
GAP II (n = 50) 56%
mGAP II (n = 71) 53%
GAP III (n = 27) 65%
mGAP III (n = 17) 84%
Fig. 3 a Kaplan–Meier survival curve analysis demonstrating a
relationship between TBR (cut-off value of 4.9 =median) and survival
in IPF patients after cross-validation. b Kaplan–Meier survival curve
analysis demonstrating a relationship between GAP index (cut-off value
of 4) and survival in IPF patients. cKaplan–Meier survival curve analysis
demonstrating a relationship between GAP stage (cut-off value of II) and
survival in IPF patients
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patients, we identified IPF patients that have a better outcome
(similar to GAP II) than the other GAP III patients, whose 3-
year mortality was nearly 90%. Likewise, there were patients
in GAP stage I that had high 18F-FDG uptake, whose outcome
was so poor that they may have benefited from treatment.
Currently, IPF patients with FVC of 80% predicted and above
are considered to have mild disease and treatment with
pirfenidone or nintedanib is not recommended in the UK by
the National Institute of Clinical Excellence [14, 15].
However, there was evidence of benefit of anti-fibrotics even
in patients with mild disease (FVC > 80% predicted) in the
original studies [16, 17]. Our data show (see supplement
Fig. 1) that a high pulmonary TBR may identify a sub-group
of patients that have a poor survival despite only mildly im-
paired lung function (FVC > 80% predicted); compared to a
group of patients with moderately impaired lung function
(FVC < 80% predicted) that progress slowly. Thus, the use
of 18F-FDG PET in this context raises the possibility of
selecting patients for pirfenidone or nintedanib in a wider
patient population.
Given the heterogeneous outcome of IPF patients, pre-
dictors of mortality in these patients are important for
many reasons. Patients may need to understand their prog-
nosis to plan for the future and assist them in their
decision-making before taking experimental therapeutics.
The patients’ physicians need information to determine the
required intensity of follow-up, to enable them to balance
the risks of entering their patients into drug trials versus the
possible benefits, and also guide them in the timing of
referral for lung transplant assessment and the listing of
patients on an active transplant waiting list. As such, we
show that those IPF patients with a pulmonary FDG uptake
with a TBR > 4.9 have twice the risk of death compared to
those with low measurements (see Cox models in the
Results section above).
Given the inherent problems in using one modality for
prognosis there has been much interest in clinical models of
risk prediction that take into account age, sex, lung function,
and other parameters, such as imaging in some cases, to build
a risk score. These have been aimed mainly at IPF, although
the original GAP (gender, age, physiology) model has been
modified for use across all ILDs and shown to perform well
[10, 22, 23]. However, even using these models, there current-
ly remains a lack of survival endpoints. This has prompted the
drive for serum biomarkers that can prospectively predict pa-
tients at most risk of disease progression. For example, in the
PROFILE study, concentrations of 11 novel epitopes derived
from matrix metalloprotease (MMP)-degraded ECM proteins
were related to subsequent progression of IPF [24]. Future
studies may be aimed at seeing if combinations of clinical
models, serum biomarkers, and functional imaging can further
refine the theranostic approach in IPF.
Since the prognosis is generally poor in IPF, effective treat-
ments are required and the development of new therapeutic
agents is urgently needed. However, at present, there is a lack
of useful biomarkers to detect or monitor disease activity in
IPF or predict survival. Using the currently available clinical
predictors, such as GAP and survival data, trials of novel
agents will be long in duration and require costly clinical
studies [3, 4, 25]. Therefore, if the pulmonary uptake of 18F-
FDG on PET is associated with survival in IPF patients, it
would be interesting to investigate whether this could be a
potential cost-effective response biomarker for drug
development.
HRCT remains the main diagnostic imaging investigation
in IPF. However, there are more limited data showing the
Fig. 4 KM-derived survival
curves from the modified GAP
groups showing that PET can
refine the mortality prediction
(see also Fig. 3b and c, and
Table 3 above). *The difference in
the survival curves based on the
PET modified GAP stage yielded
a p < 0.001 (log-rank test)
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prognostic use of HRCT. Previous investigations have provid-
ed associations between survival data and visual scoring/
grading systems of HRCT findings in acute exacerbation, a
specific situation in which the overall prognosis is generally
dire [26, 27]. In the more general prognostic bio-marker role
of baseline HRCT in ILD, one single-center study showed that
baseline HRCT could be used to predict survival [28] and a
large study of mild-to-moderate IPF showed that the extent of
honey combing and reticulation was inversely associated with
survival [29]. The latter study was a post hoc analysis to a
phase III intervention study and thus potentially complicated
using pharmacological agents. Another HRCT study has been
used to directly assess response to therapy as well as survival
[30]. More recently, quantitated CT has been explored with
some interesting findings. In one such retrospective IPF study,
textural CT patterns derived from HRCT were shown to cor-
relate with lung function [31]. In another, a computer algo-
rithm was used to quantify CT changes in IPF patients, and
these were shown to be associated with mortality and add
further information to the combined physiological index
(COI) or GAP scores [32]. Similarly, another group used tex-
tural analysis using dual-energy contrast CT in patients with
ILD, showing mortality associations [33]. In contrast, our im-
aging approach is novel and has the potential advantage of
exploiting the functional data and sensitivity of PET [34].
Nonetheless, it is recognized that the underlying CT changes
may affect the PET CT signal per se, as has been previously
recognized [35]. Differences observed in SUVas used in this
paper could be due to a combination of differences in tracer
uptake and tissue density. However, it is worth noting that the
SUV measures presented in this paper can be computed with
standard software.
Although HRCT is essential for diagnosis, the PET signal
was important for prognosis when measured from regions
where HRCT lung parenchyma findings were normal. In a
retrospective analysis, it was shown that increased 18F-FDG
in normal lung was associated with poor survival in ILD pa-
tients [36]. This is in keeping with another study that showed
that in IPF patients normal lung parenchyma as demonstrated
on HRCT showed higher 18F-FDG uptake than control pa-
tients [37]. This may suggest that PET can detect disease sig-
nals before anatomical changes on HRCTare revealed, and as
such, PET, in addition to detecting severe disease, may be
detecting early or mild disease.
The precise cellular mechanisms underlying the ob-
served FDG-PET signal in IPF are as of yet unknown.
We and others have considered the possibility that the
FDG signal is generated by inflammatory cells in the al-
veolar space that may not be seen on lung biopsy, and act
as sentinels of lung damage. However, there is accumu-
lating evidence that glucose uptake plays a fundamental
role in the fibrotic process. The facilitative glucose trans-
porter 1 GLUT-1 is up-regulated on fibroblasts in the
fibrotic regions of both patients with IPF and mice that
are subjected to a fibrosis-inducing bleomycin treatment
[38]. GLUT1 is induced by transforming growth factor
(TGF)-β in fibroblast lines and primary cells and is re-
quired for the profibrotic effects of T GF-β. Further evi-
dence that metabolically active cells, taking up increased
amounts of glucose, are present in the lungs of IPF pa-
tients come from the increased lactic acid levels found in
the lungs of IPF patients compared to healthy and COPD
controls [39]. This lactic acid may contribute to the path-
ogenesis of the disease by activating TGF-β and driving
collagen production from fibroblasts [39]. Regardless of
the underlying mechanism, the utility of FDG-PET as a
prognostic marker in IPF remains valid and reflects the
presence of metabolically active cells in the lungs of these
patients.
There are many technical factors that need to be appre-
ciated in this type of imaging study, such as density-
induced artefacts, a varying blood fraction in the lung,
and respiratory motion due to free breathing during the
acquisition. The methodological considerations involved
in tackling these challenges have been dealt with elsewhere
[7, 8, 40–42]. Furthermore, respiratory gating would allow
reducing the effect of the breathing, albeit at the expense of
increased noise. Despite these challenges, we were able to
make significant survival observations using routine PET
measurements. There are a number of standard clinical 18F-
FDG measurements that can be acquired. The three mea-
surements we have performed are easily implemented and
are used to quantify the glucose uptake in routine clinical
practice. The advantage of assessing glucose uptake in this
way is that use of a background 18F-FDG region allows
standardization of measurements. We show that TBR in
IPF patients is the most prognostic of our three measure-
ments. Our results are in keeping with the previous find-
ings from a dual time point imaging PET study (imaging at
1 and 3 h post-injection of 18F-FDG), where a single SUV
measurement at 1 h was not found to have an association
with survival. However, with the addition of increased
SUV information, (the additonal data from the 2nd time
point in the dual time point study, and the ratio of SUVs
in our study) it did allow for an association with survival
[43]. In another interesting study [44], there was a lack of
association between SUVmax (and mean) with IPF survival,
in keeping with our findings. Only more complex measure-
ments of 18F-FDG (e.g., tumor lesion glycolysis and met-
abolic lesion volume), which are more arbitrary, showed
any significant survival associations.
Other study limitations include the fact that the timing of the
PET study was not always at the time of diagnosis and thus
patients would have varying stages of disease. Our data imply
that prognosis may be determined at various stages of disease.
What would be of particular interest would be an investigation
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of the use of serial PET scanning in the disease setting.
Similarly, serial measurements in PFT (e.g., FVC) and other
indicators (e.g., respiratory, hospitalization, preceding change
in physiology, disease trajectory some of which are not validat-
ed biomarkers) could be assessed in the future. However, it is
recognized that there is inherent variability in PFT and PET
measurements that serial imaging cannot entirely correct.
Another challenge in the IPF patient population is the difficulty
in differentiating the contribution of IPF to death from co-mor-
bidities, further compounded by the regular palliative setting of
IPF patients at the end of life. For these reasons, we adopted a
recognized approach in IPF, and used the all-cause mortality as
also in the original GAP analyses [16]. Finally, minimizing bias
is challenging in this type of study. The use of test and valida-
tion populations can be helpful, but instead we used a k-fold
cross-validation technique, which is appropriate in a population
size such as in our study [25]. We further minimized bias using
median value as cut-offs.
Conclusions
We have shown that high pulmonary uptake of 18F-FDG
(TBR) is associated with mortality in our population of IPF
patients. These PET findings were statistically independent of
GAP survival associations, but were also shown to act syner-
gistically with the GAP classification to help further risk strat-
ify IPF patients.
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